| Identification | Back Directory | [Name]
N-(trans-3-[5-[(1R)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]cyclobutyl)-3-phenyl-1,2-oxazole-5-carboxamide | [CAS]
1953130-87-4 | [Synonyms]
PTI-428
Nesolicaftor
PTI-428; PTI 428; PTI428;
5-Isoxazolecarboxamide, N-[trans-3-[5-[(1R)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]cyclobutyl]-3-phenyl-
N-(trans-3-[5-[(1R)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]cyclobutyl)-3-phenyl-1,2-oxazole-5-carboxamide | [Molecular Formula]
C18H18N4O4 | [MDL Number]
MFCD31813908 | [MOL File]
1953130-87-4.mol | [Molecular Weight]
354.36 |
| Chemical Properties | Back Directory | [density ]
1.40±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 250 mg/mL (705.50 mM) | [form ]
Solid | [pka]
12.22±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Nesolicaftor (PTI-428) is a specific cystic fibrosis transmembrane conductance regulator (CFTR) amplifier[1]. | [References]
[1] Mijnders M, et al. Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis. Curr Opin Pharmacol. 2017 Jun;34:83-90. DOI:10.1016/j.coph.2017.09.014
[2] Arianna Venturini, et al. Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene. Int J Mol Sci. 2021 Nov 4;22(21):11972. DOI:10.3390/ijms222111972 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|